Comparison of Topical Antiviral Agents for Labial Cold Sores (Herpes Labialis)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified April 2007 by Hadassah Medical Organization.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by:
Hadassah Medical Organization
ClinicalTrials.gov Identifier:
NCT00467662
First received: April 17, 2007
Last updated: April 30, 2007
Last verified: April 2007
  Purpose

Recurrent cold sores - herpes simplex labialis (HSL) occurs in 20-40% of the US population and patient seek treatment because of the discomfort and visibility of the lesion although it is a self limiting disease. The purpose of this study is to check the safety, Efficacy and convenience of Use of the Natural Agent "Superlysin Gel" as Treatment for Herpes Labialis in Comparison to Acyclovir 5% and Docozanole 10%.


Condition Intervention Phase
Reccurent Herpes Labialis
Drug: Acyclovir 5%
Drug: Docosanol 10%
Device: Superlysine gel
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Factorial Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: The Safety, Efficacy and Convenience of Use of the Natural Agent "Superlysin Gel" as Treatment for Herpes Labialis in Comparison to Acyclovir 5% and Docozanole 10%.

Resource links provided by NLM:


Further study details as provided by Hadassah Medical Organization:

Primary Outcome Measures:
  • Reducing healing process and duration of cold sores using superlysin gel

Estimated Enrollment: 75
Detailed Description:

Study design:

-Double blinded non-inferiority prospective parallel-group, intend to treat trial. Enrolment of 75 patients (25 randomized for each group). - Approval of the Institutional Ethical Review Board -

Study design:

- Patient characteristics (selected) and historical information assessment including: Race, average episode duration from patient history Duration of most recent previous episode Time since last onset of oral-facial herpes simplex Time since first onset of oral-facial herpes simplex Does patient experience localized prodrome?

  • Experiment duration; 5 to 10 days
  • 4 visits (days 1, 3,6,10)
  • 5 application /day for each derivative
  • Documentation Metric digital images of localized area signs at each visit Clinical assessment of prodrome/erythema, papule, vesicle, ulcer, crust, or healed skin (with or without residual erythema) Visual analogue scale (VAS) for subjective assessment of pain, burning, itching or tingling at each visit
  • Calculation of primary efficacy end point (time to healing); from the date and time of the initiation of therapy until the date and time of the clinic visit at which complete resolution of all local signs and symptoms, i.e. the lesion had aborted or complete healing had occurred (censored at day 10)
  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  • Signed informed consent
  • Age range (yrs) 18-70
  • Gender ; Males and females
  • Health status; immuno-competent
  • Clinical history of HSL with at least two recurrences during the past 12 months. The most recent previous episode must have healed at least 14 days before screening.
  • Less than 12 hours after prodrome initiation (i.e. local erythema w/o blistering, tingling and or burning sensation, soreness)

Exclusion criteria:

  • Pregnant women
  • Mentally disabled
  • No intra-oral lesions, or lesions above the nostrils and below the chin
  • No topical steroid use and no systemic antiviral current treatments within 7 days before the study
  • No known allergies to topical cosmetics
  • No use cosmetics on or around the mouth during the treatment period
  • No concomitant use of systemic corticosteroids or other drugs known to induce immune stimulation or immune suppression
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00467662

Contacts
Contact: Doron J Aframian, DMD, PhD 0097226776151 Daframian@yahoo.com

Sponsors and Collaborators
Hadassah Medical Organization
Investigators
Study Chair: Doron Aframian, DMD,PhD Salivary Gland Clinic, Department of Oral Medicine The Hebrew University-Hadassah School of Dental Medicine Jerusalem, Israel P.O.B 12272, Zip code 91120
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00467662     History of Changes
Other Study ID Numbers: 376.hmo-ctil
Study First Received: April 17, 2007
Last Updated: April 30, 2007
Health Authority: Israel: Ministry of Health

Additional relevant MeSH terms:
Herpes Labialis
Herpes Simplex
Herpesviridae Infections
DNA Virus Infections
Virus Diseases
Skin Diseases, Viral
Lip Diseases
Mouth Diseases
Stomatognathic Diseases
Skin Diseases, Infectious
Skin Diseases
Acyclovir
Antiviral Agents
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on September 22, 2014